Abstract
CRISPR-Cas9 has emerged as a groundbreaking genome editing tool with significant implications for pharmacology. This technology allows for precise modifications of genomic DNA, offering a new approach to drug discovery, gene therapy, and the understanding of disease mechanisms. The integration of CRISPR-Cas9 into pharmacological research is transforming traditional drug development pipelines and enabling the identification of novel drug targets. This article explores the mechanisms of CRISPR-Cas9, its pharmacological applications, challenges, and the future potential in personalized medicine and therapeutic development.
All articles published in the American Journal of Pharmacy and Pharmacology are licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows others to:
-
Share — copy and redistribute the material in any medium or format
-
Adapt — remix, transform, and build upon the material for any purpose, even commercially
Under the following terms:
-
Attribution — Appropriate credit must be given to the original author(s) and source, a link to the license must be provided, and any changes made must be indicated.
By submitting their work, authors agree to these licensing terms and retain copyright of their articles.